Single-agent Smac-mimetic compounds induce apoptosis in B chronic lymphocytic leukaemia (B-CLL)

Cinzia Scavullo, Federica Servida, Daniele Lecis, Francesco Onida, Carmelo Drago, Luca Ferrante, Pierfausto Seneci, Wilma Barcellini, Marta Lionetti, Katia Todoerti, Antonino Neri, Domenico Delia, Giorgio Lambertenghi Deliliers

Research output: Contribution to journalArticle

Abstract

Defective apoptosis is a hallmark of the progression of B chronic lymphocytic leukaemia (B-CLL). Smac-mimetics have been shown to induce apoptosis in several tumours. We describe the in vitro pro-apoptotic activity and regulation of the molecular pathway induced by new Smac-mimetics in B-CLL. The cytotoxic effect was significantly higher in B-CLL samples than in healthy controls. No significant synergistic effect was observed in combined treatment. In conclusion one of our compounds (Smac66), used as monotherapy and not in combination, is highly active against B-CLL cells thus suggesting a promising therapeutic potential as a new class of antileukemic drugs in haematology.

Original languageEnglish
Pages (from-to)809-815
Number of pages7
JournalLeukemia Research
Volume37
Issue number7
DOIs
Publication statusPublished - Jul 2013

    Fingerprint

Keywords

  • Apoptosis
  • B-CLL
  • Caspases
  • Smac-mimetics
  • Therapy
  • TNF

ASJC Scopus subject areas

  • Cancer Research
  • Hematology
  • Oncology

Cite this

Scavullo, C., Servida, F., Lecis, D., Onida, F., Drago, C., Ferrante, L., Seneci, P., Barcellini, W., Lionetti, M., Todoerti, K., Neri, A., Delia, D., & Deliliers, G. L. (2013). Single-agent Smac-mimetic compounds induce apoptosis in B chronic lymphocytic leukaemia (B-CLL). Leukemia Research, 37(7), 809-815. https://doi.org/10.1016/j.leukres.2013.03.016